A general SNP-based molecular barcode for Plasmodium falciparum identification and tracking
- Rachel Daniels†1,
- Sarah K Volkman†2, 3,
- Danny A Milner†3, 4,
- Nira Mahesh2,
- Daniel E Neafsey1,
- Daniel J Park1,
- David Rosen2,
- Elaine Angelino5,
- Pardis C Sabeti1,
- Dyann F Wirth2 and
- Roger C Wiegand1Email author
© Daniels et al; licensee BioMed Central Ltd. 2008
Received: 24 April 2008
Accepted: 29 October 2008
Published: 29 October 2008
Single nucleotide polymorphism (SNP) genotyping provides the means to develop a practical, rapid, inexpensive assay that will uniquely identify any Plasmodium falciparum parasite using a small amount of DNA. Such an assay could be used to distinguish recrudescence from re-infection in drug trials, to monitor the frequency and distribution of specific parasites in a patient population undergoing drug treatment or vaccine challenge, or for tracking samples and determining purity of isolates in the laboratory during culture adaptation and sub-cloning, as well as routine passage.
A panel of twenty-four SNP markers has been identified that exhibit a high minor allele frequency (average MAF > 35%), for which robust TaqMan genotyping assays were constructed. All SNPs were identified through whole genome sequencing and MAF was estimated through Affymetrix array-based genotyping of a worldwide collection of parasites. These assays create a "molecular barcode" to uniquely identify a parasite genome.
Using 24 such markers no two parasites known to be of independent origin have yet been found to have the same allele signature. The TaqMan genotyping assays can be performed on a variety of samples including cultured parasites, frozen whole blood, or whole blood spotted onto filter paper with a success rate > 99%. Less than 5 ng of parasite DNA is needed to complete a panel of 24 markers. The ability of this SNP panel to detect and identify parasites was compared to the standard molecular methods, MSP-1 and MSP-2 typing.
This work provides a facile field-deployable genotyping tool that can be used without special skills with standard lab equipment, and at reasonable cost that will unambiguously identify and track P. falciparum parasites both from patient samples and in the laboratory.
Nearly all malaria-associated mortality in children is due to infection with Plasmodium falciparum, which causes over 300 million clinical infections and a million deaths per year in African children under five years of age . Genome sequencing of multiple parasite isolates [2–5] indicates that the parasite population is highly diverse. Genetic diversity in P. falciparum is manifested in the form of single nucleotide polymorphim (SNPs), microsatellite repeats, insertions, deletions and a range of gene duplication events. Much of this diversity segregates independently. Analysis of the progeny from a genetic cross suggests that the parasite genome is approximately 50-fold more 'recombinogenic' than the human genome . This genetic diversity underlies the ability of the parasite to escape both immune clearance and drug treatment.
Parasite genetic variation can be exploited epidemiologically to provide a means of uniquely identifying parasites that infect individuals and to follow these parasites through the course of infection as drug or other interventions are applied. For example, these methods are useful for identifying parasites in an individual prior to treatment to later determine if post-treatment parasitaemia are the result of failure to clear the original parasites by the drug(s) (recrudescence) or of re-infection by another parasite form. These methods are critical for determining the efficacy of drugs in the field.
The first powerful and easily deployable tool for assessing the identity (i.e., genotype) of a given parasite isolated from a patient was published in 1994 by Snounou using three polymorphic loci (merozoite surface protein (msp)-1, msp-2, and glutamine rich protein, glurp) in a nested polymerase chain reaction (PCR) to identify length polymorphisms within six potential alleles (K1, MAD20, and RO33 for msp-1; IC and FC27 for msp-2; and glurp) . The technique requires gel electrophoresis, fluorescent primers in conjunction with capillary electrophoresis to resolve the length of the individual allele polymorphisms, or a Luminex fluorescent microsphere assay . The practical use of this genotyping system – whole or in part – was reviewed by Collins et al for 91 of 384 studies between 1995 and 2005, focused on antimalarial clinical trials . They conclude from this meta-analysis that the great deal of variation found in the use and interpretation of this system was statistically related in multivariate analysis to the polyclonality of infections, treatment employed, geographic location, and duration of follow-up . Pyrosequencing has also been used to evaluate short stretches of DNA sequence from patient samples surrounding a single locus to quantify alleles and haplotypes of MSP-1 in a population . A modification of the standard MSP/GLURP genotyping technique, the heteroduplex tracking assay, demonstrated an ability to track complex infections in an endemic area with high polyclonality (3.82 per patient). However, this assay currently depends on the use of radioactive tracers, making it difficult or impossible to employ in many field settings . Although others have offered refinements on these basic approaches or focused on microsatellite polymorphisms for determining polyclonality, or some combination thereof, the current approaches are either labour-intensive, difficult to carry out in a field setting, or require subjective interpretation [8, 9].
As part of an ongoing effort to map genomic diversity of P. falciparum, genome sequencing has identified more than 112,000 SNPs from about 18 parasite genomes [10–12]. Current technology has made genotyping of SNPs by real-time PCR using dual probes in an end-point detection assay a standard practice. We filtered the discovered SNPs to create a panel of genotyping assays capable of defining a "molecular bar code" or signature for a given malaria parasite. Ideal SNPs for such an assay panel segregate independently, are common (i.e. exhibit a high minor allele frequency (MAF)) and are broadly distributed across the genome. The assay method has to be easy to use, inexpensive, and applicable to a wide variety of both field and laboratory derived material. The TaqMan system was choosen as a genotyping methodology, with the eventual goal of developing these assays into a simple, end-point PCR process that could be performed in the field where a PCR machine and a plate reader were available.
This work describes the first P. falciparum molecular bar code composed of 24 SNPs that in combination create a unique fingerprint or signature for a parasite genome. This methodology can be applied to a variety of laboratory and field samples including direct culture-adapted material, genomic DNA, frozen blood from patients or filter-paper collected samples with over 99% success. This methodology is extremely sensitive, requiring only a small amount of input material. Human DNA within the sample does not interfere with the results. This molecular barcode is also capable of identifying mixtures of parasite genomes within samples that would otherwise be identified as single parasite infections by conventional msp-1 and msp-2 genotyping, and thus provides a robust, inexpensive, facile method for evaluating parasite genomes within patient samples.
SNP selection and assay design
SNPs were chosen for assay development using two criteria – technical assessment of predicted assay performance and population MAF. All assayed SNPs were selected from a superset of approximately 2,100 SNPs previously discovered through comparative genome sequencing  which were found to be assayable on an Affymetrix genotyping chip (Neafsey et al., manuscript in review). The initial set of SNPs was sent to Applied Biosystems (AB) for evaluation of the likelihood of TaqMan assay success. The SNPs determined to be most assayable technically were then examined for MAF in two populations: Senegal and Thailand. MAF was determined from a total of up to 22 patient isolates from Senegal and 16 patient isolates from Thailand. MAF was only calculated for SNPs that were successfully typed in at least five isolates from each population. SNPs exhibiting an average MAF of at least 35% across the two populations were chosen for final assay development so as to maximize coverage across chromosomes while maintaining a homogenous melting temperature (Tm). SNPs were also assessed for their independence from one another to ensure that none of the loci were tightly linked. A total of 88 independent assays were designed and a final set of 24 assays were chosen to minimize the likelihood of obtaining identical bar codes from closely related isolates, while providing uniform quantitative performance. TaqMan Minor-Groove-Binder (TaqMan-MGB) probes were chosen for the MGB moiety's ability to offer improved performance with shorter probes through stabilization of the hybridized probe and subsequently higher reaction melting temperatures. The numbering corresponding to the 24 SNPs selected for this assay reflect the chromosome number and coordinate number of the 3D7 genome from version 5.0 of PlasmoDB.
To evaluate these methodologies under conditions as variable as those found in the field at malaria endemic sites, we used the following sample types: whole blood mixed with parasites in culture (either depleted or not depleted of white blood cells (WBCs) using PlasmodiPur), whole blood spotted on FTA paper from patients with smear-positive P. falciparum infection, frozen whole blood from infected patients (depleted or not of WBCs using PlasmodiPur), fresh and frozen parasite culture, residual wash from a vial of thawed parasites (previously frozen in glycerolyte), purified genomic DNA, and whole genome amplification (WGA) products both from purified genomic DNA and from patient samples described above. All samples were collected with informed consent under human subject guidelines and approved by the relevant institutional review boards. Historical culture adapted lines used in this study were evaluated by the institutional review board and deemed exempted under category 4 of the 45 CFR 46.101(b). For WGA samples, Qiagen REPLI-g (Catalog # 150045) was performed according to the manufacturer's protocol. Human DNA (Bioline Catalog # BIO-35025) was used as a control and mixed with various samples derived from in vitro culture to assess whether human DNA would interfere with assay results.
From FTA paper preserved whole blood samples, DNA was extracted using either QIAmp DNA Blood Mini Kit (Qiagen Catalog # 51106) or Gensolve blood spot kit (GenVault Catalog # GVR-50) using three-6 mm punches for each method. From whole blood samples that had been frozen, DNA was extracted using QIAmp DNA Blood Mini Kit (Qiagen Catalog #51106) and Promega Maxwell 16 Blood DNA Purification Kit (Promega Catalog # AS1010). From parasite culture, DNA was extracted using Qiagen g-100 (Catalog # 13343), DNAzol Direct (Molecular Research Center, Inc. Catalog # DN131) or by simply placing an aliquot of culture directly into the reaction without any extraction method (i.e., parasitized red blood cells directly from culture were diluted 1:100 and 0.5 – 1 μl per 5 μl reaction was used).
To distinguish between the amount of DNA derived from human and that from malaria sources in a whole blood sample, we developed a quantification method, both for human DNA, and for P. falciparum DNA using the TaqMan technology. To identify sequences for the malaria probe, we used data available from the 3D7 reference malaria genome , the database of SNPs from three sources [10–12], and expression data from in vitro and ex vivo experiments . PF07_0076, a 519 bp gene encoding protein of unknown function on chromosome 7, was selected and sequence data from 3D7 was used to design TaqMan-MGB primers (forward: CGACCCTGATGTTGTTGTTGGA; and, reverse: GGCTTTTTTCCATTTCTGTAGTTAAGATTCA) and reporter sequence (CAACAGCTCCAAAATAT) probes from the highly conserved region of the gene.
HB3 genomic DNA was used as control in a series of 8 different dilutions: 30 ng, 10 ng, 3 ng, 1 ng, 0.3 ng, 0.1 ng, 0.03 ng, and 0.01 ng of DNA (based on OD260) per 5 μl reaction. All quantification was done in triplicate. Samples were processed for quantification depending upon the type of specimen. Purified genomic DNA from culture was quantified by either the picogreen or spectrophotometric assay and diluted to approximately 0.4 ng/μl in sterile water for optimal amplification signal; 2.5 μl was used per reaction. Purified DNA from blood spots was diluted 1:10 and 1 μl per 5 μl reaction was used. Parasitized red blood cells directly from culture or from fresh or frozen blood were diluted 1:100 and 0.5–1 μl per 5 μl reaction was used.
A master mixture was prepared using 2.25 μl Master Mix (Applied Biosystems Catalog # 4364343) and 0.250 μl of 20× Pf07_0076 pre-mixed quantification assay was used per reaction plus 10% to account for potential pipetting loss. All reagents were stored on ice with a foil cover while preparing mixes and dilutions. Controls and samples were loaded into 384-well PCR plates (total volume of DNA and water was 2.5 μl in a 5 μl reaction) followed by addition of the master mixture. Plates were loaded into an AB 7900 HT and run for Absolute Quantification: 50°C for 2 minutes, 95°C for 10 minutes, 95°C for 15 seconds, 60°C for 1 minute, repeat steps 2–4 for 40 cycles. For low DNA concentrations (e.g., blood spots or direct culture), cycle number was increased to 50.
Quantification of human genetic material was accomplished using Applied Biosystem's commercially available RNase P Control Reagent (AB Catalog # 4316844). A standard curve at the same concentrations previously discussed was generated using human genomic DNA from Bioline (Catalog # BIO-25025).
msp-1 and msp-2 genotyping
msp-1 and msp-2 genotyping was performed in triplicate using the standard nested PCR method . Briefly, 1 μl of sample (or about 5 ng of gDNA) was amplified with primers for the msp-1 and msp-2 loci with products approximately 900 and 700 bp. In the second round of PCR, internal primers for the three alleles of msp-1 (i.e. K1, MAD20, and RO33) and the two alleles of msp-2 (i.e. FC27 and 3D7/IC) were performed in separate reactions. The resulting products were resolved by electrophoreseis through 1.5% agarose gel in 1× TBE and scored for the number of alleles per sample.
Following quantification, samples were normalized for concentration with the minimum parasite DNA concentration per well for successful calling of all 24 SNPs in the molecular bar code as low as 1 pg per 5 μl reaction. For each reaction, template and water in a total volume of 2.5 μl was added to a 2.5 μl mix made up of 0.125 μl 40× SNP assay and 2.5 μl Master Mix (AB Catalog # 4364343) in a 384-well optical PCR plate and mixed, for a total reaction volume of 5 μl. The plate was covered with an optical plate seal and amplified in an ABI 7900 HT (ABI standard PCR protocol: 95°C for 10 minutes, 95°C for 15 seconds, 60°C for 1 minute, repeating steps 2–4 for 40 cycles). For samples containing low DNA concentrations (e.g. blood spots or direct culture), cycles were increased in number to 50. Following amplification, the samples were analyzed using Applied Biosystem's proprietary Allelic Discrimination and Absolute Quantitation software included in their SDS 2.x software suite using both 2.2.2 and 2.3.x versions. A good assay result for allelic discrimination trials was determined when the scattergram showed clearly separated clusters distinct from negative controls included on every plate. Successful results for quantitation were determined when the amplification curve had the anticipated log-growth curve for one or both alleles (in mixtures) that was clearly distinct from the background controls. A complete protocol can be found as Additional File 1.
The parasite quantification probe corresponds to a region of the PF07_0076 gene (see Materials and Methods), which exhibits low genetic variation and is a single copy gene within a variety of parasites derived both from laboratory culture and patient samples . For the purposes of standardizing the quantification, a parasite DNA standard using HB3 DNA that was used as a control for all assays in the analysis was created. Quantitation of this reference DNA sample was linear over a large quantitation range and was generally comparable to both standard pico green and spectrophotometric methods. This method has the advantage of being able to quantify P. falciparum DNA within a patient sample that contains human DNA. Thus, the qPCR method showed more consistency for assessing P. falciparum DNA contributions from sample to sample and across dilutions of samples than the fluorescent or spectrophotometric methods. To confirm that the parasite and human quantification probes worked independently, we created standard mixtures of genomic DNA from P. falciparum and human and demonstrated that quantification within the mixtures was consistent with quantification of both pure parasite and pure human DNA samples. Thus, the TaqMan quantification probe for P. falciparum was reliable and consistent both in samples containing parasite DNA alone and in samples containing a mixture of parasite and human DNA (Additional File 5).
The molecular bar code assays were applied to 114 independent parasite lines (see Additional File 10) to identify samples with mixed genomes and derive unique signatures for the cultured parasite lines comprised of a single genomic background. The methodology worked on > 99% of samples requiring as little as 5 ng of genomic DNA. The utility of the bar code assay for patient-derived samples was determined by assessing its performance across a variety of sample types. DNA derived from culture-derived samples, from patient-derived samples, and from experimental samples were tested in the assay. For the culture-derived samples either genomic DNA derived from the parasite or direct culture material was used. For the patient-derived samples either blood spots dried onto filter paper or frozen blood samples were used. The experimental samples were mixtures of genomic DNA (parasite and human or multiple parasites), mixtures of culture with whole human blood, or WGA material from a variety of samples. The molecular bar code was robust and reliable for all of these sample types. In general a reliable bar code genotype was detected with less than 5 ng of genomic DNA from culture-adapted or patient-derived material. WGA products from a variety of samples (extracted DNA from culture or patient samples) also reliably and reproducibly provided a molecular bar code with the minimum input of ~1 ng DNA.
For both laboratory and field-based studies, it is of paramount importance to be able to identify and track parasites. In the field, a simple and inexpensive method to identify parasites within a patient sample pre- and post-treatment is critical for epidemiologic studies and therapeutic efficacy trials. In the lab, problems of mis-identification and cross-contamination have plagued both mammalian tissue culture [16, 17] and parasite tissue culture for decades [18, 19]. For example, it has been previously noted that the 106/1, FCB and FCR3 P. falciparum lines are nearly identical genetically, quite inconsistent with their presumed geographic origins. Establishing the provenance of cultured parasites and maintaining their integrity is essential to studies that depend on proper geographic identity and/or clinical observations attributed to those parasites.
This work describes the development of a molecular barcode assay that leverages genome-wide diversity data to create a concise and unique signature for every parasite genome. This field-deployable method employs 24 TaqMan genotyping assays of independently segregating SNPs sampled from across the genome, and requires only a small amount of easily collected material such as filter-paper-collected blood spots. The same SNPs can, of course, be assayed by any other available method. The TaqMan system was chosen for its robustness, potential to deploy with common laboratory equipment, and straightforward data interpretation.
Although this method is based upon currently available sequence data, it is inherently adaptable in that new genomic diversity information from yet-unsampled P. falciparum populations can be used to generate assays suited for strain identification in those populations in the event the current method is insufficient. Although the assays were designed based on data from Africa and Thailand, the chosen set of SNPs also performed well to distinguish parasites from Brazil. This method can also flexibly incorporate assays for phenotypes of interest, such as SNPs in pfcrt and dhfr known to directly confer drug resistance, or assays at non-polymorphic residues that quantitatively assess copy number of genes such as pfmdr1 that have been associated with some forms of drug resistance. As new markers of different phenotypes are identified through QTL or association studies, this simple method can be extended to include these new markers. Given that this method is simple, inexpensive and field-deployable, it can greatly enhance our ability to follow epidemiological or therapeutic efficacy trials. Furthermore, this simple and inexpensive assay system can be used in the laboratory to follow parasites through the culture-adaptation and subsequent subcloning processes to ask questions about selection and competition as parasites grow in mixtures.
As the molecular bar code is applied and refined it will be critical to continue to make comparisons with standard genotyping currently in the field including the MSP-1, MSP-2, GLURP combination or microsatellite genotyping. Though these initial assays are able to distinguish the relative proportions of major and minor alleles in simple mixtures, we need to improve upon the ability to detect multiple genomes within patient samples. Among culture-adapted parasite samples the molecular bar code was useful for tracking parasites during the culture-adaptation and subcloning process. Finally, this method was easily able to detect instances of cross contamination in the laboratory, thus providing a powerful quality control step within the laboratory setting.
In conclusion, TaqMan technology is a methodology that allows rapid, reliable, and inexpensive genotyping of alleles across the P. falciparum genome, and may be applied to genotyping genetic loci that are important for drug resistance, invasion, virulence, and immunity. This methodology has been applied to develop a molecular bar code that provides a unique signature for the purposes of tracking parasites in the laboratory and within patient samples. This method provides a uniform and reliable method to genotype the identity of parasites when compared to conventional MSP-1 and MSP-2 genotyping, is able to identify mixtures of alleles in a sample that would otherwise be classified as containing a single parasite genome. This methodology can be applied to the identification of drug resistance mutations and for genotyping parasites in drug treatment trials to evaluate for recrudescence or reinfection.
List of abbreviations
Single Nucleotide Polymorphism
Minor Allele Frequency
Polymerase Chain Reaction
Minor Groove Binder
White Blood Cells
Whole Genome Amplification
Ethylene Diamine Tetraacetic Acid
Tris Boric Acid EDTA
Merozoite Surface Protein
Glutamine Rich Protein
We wish to thank all members of the sample collection team in Senegal (Ambroise Ahouidi, Lamine Ndiaye, Oumar Ly, Younouss Diedhiou, Theophile Sene, Amadou Mbaye and Dior Diop), and in Malawi (Terrie Taylor, Karl Seydel, Jacqui Montgomery, Edson Dembo, Malcolm Molyneux, and Stephen Rogerson), as well as all the patients and their families for allowing us to collect blood for the isolation of the parasite. We thank all the members of the Broad Sequencing Platform and the Affymetrix genotyping platform at the Broad. Thanks to Amanda Lukens and Gilberto Ramirez for help with sample preparation, and to Alejandro Miguel Katzin, Valnice de Jesus Peres, and Emilia A. S. Kimura for collection and culture-adaptation of parasites from Brazil. Thanks to Steve Schaffner for a critical reading of the manuscript. We thank MR4 for providing us with malaria parasites contributed by the following depositors: W.E. Collins (MRA-347, MRA-362); D.E. Kyle (MRA-157, MRA-159, MRA-176, MRA-202, MRA-204, MRA-205, MRA-206, MRA-207, MRA-284, MRA-285); L.H. Miller and D. Baruch (MRA-326, MRA-330); X. Su (MRA-818, MRA-821, MRA-822); W. Trager (MRA-732, MRA-733); D. Walliker (MRA-151, MRA-152, MRA-153, MRA-200); T.E. Wellems (MRA-155, MRA-156, MRA-309, MRA-464) and Y. Wu (MRA-201). The authors are supported by a grant from the National Institutes of Health, SPARC funding of The Broad Institute of MIT and Harvard, the Burroughs-Wellcome Fund, The Bill and Melinda Gates Foundation, the NIAID Microbial Sequencing Center, the Ellison Medical Foundation, Fogarty International and the Exxon Mobil Foundation. DM was supported by NIH K23 grant [K23AIO72033-01].
- Global Fund to Fight AIDS, Tuberculosis and Malaria: The global malaria situation: current tools for prevention and control. [http://ftp.who.int/gb/archive/pdf_files/WHA55/ea55id6.pdf]
- Su XFM, Huang Y, Huynh CQ, Liu A, You J, Wootton JC, Wellems TE: A genetic map and recombination parameters of the human malaria parasite Plasmodium falciparum. Science. 1999, 286 (5443): 1351-1353. 10.1126/science.286.5443.1351.View ArticlePubMedGoogle Scholar
- Viriyakosol SSN, Petcharapirat C, Petcharapirat P, Jarra W, Thaithong S, Brown KN, Snounou G: Genotyping of Plasmodium falciparum isolates by the polymerase chain reaction and potential uses in epidemiological studies. Bull World Health Organ. 1995, 73 (1): 85-95.PubMed CentralPubMedGoogle Scholar
- Dent AE, Yohn CT, Zimmerman PA, Vulule J, Kazura JW, Moormann AM: A polymerase chain reaction/ligase detection reaction fluorescent microsphere assay to determine Plasmodium falciparum MSP-119 haplotypes. Am J Trop Med Hyg. 2007, 77 (2): 250-255.PubMed CentralPubMedGoogle Scholar
- Collins WJ, Greenhouse B, Rosenthal PJ, Dorsey G: The use of genotyping in antimalarial clinical trials: a systematic review of published studies from 1995–2005. Malar J. 2006, 5: 122-10.1186/1475-2875-5-122.PubMed CentralView ArticlePubMedGoogle Scholar
- Takala SL, Smith DL, Stine OC, Coulibaly D, Thera MA, Doumbo OK, Plowe CV: A high-throughput method for quantifying alleles and haplotypes of the malaria vaccine candidate Plasmodium falciparum merozoite surface protein-1 19 kDa. Malar J. 2006, 5: 31-10.1186/1475-2875-5-31.PubMed CentralView ArticlePubMedGoogle Scholar
- Kwiek JJ, Alker AP, Wenink EC, Chaponda M, Kalilani LV, Meshnick SR: Estimating true antimalarial efficacy by heteroduplex tracking assay in patients with complex Plasmodium falciparum infections. Antimicrob Agents Chemother. 2007, 51 (2): 521-527. 10.1128/AAC.00902-06.PubMed CentralView ArticlePubMedGoogle Scholar
- Anderson TJ, Su XZ, Bockarie M, Lagog M, Day KP: Twelve microsatellite markers for characterization of Plasmodium falciparum from finger-prick blood samples. Parasitology. 1999, 119 (Pt 2): 113-125. 10.1017/S0031182099004552.View ArticlePubMedGoogle Scholar
- Greenhouse B, Myrick A, Dokomajilar C, Woo JM, Carlson EJ, Rosenthal PJ, Dorsey G: VALIDATION OF MICROSATELLITE MARKERS FOR USE IN GENOTYPING POLYCLONAL PLASMODIUM FALCIPARUM INFECTIONS. Am J Trop Med Hyg. 2006, 75 (5): 836-842.PubMed CentralPubMedGoogle Scholar
- Volkman SK, Sabeti PC, DeCaprio D, Neafsey DE, Schaffner SF, Milner DA, Daily JP, Sarr O, Ndiaye D, Ndir O, Mboup S, Duraisingh MT, Lukens A, Derr A, Stange-Thomann N, Waggoner S, Onofrio R, Ziaugra L, Mauceli E, Gnerre S, Jaffe DB, Zainoun J, Wiegand RC, Birren BW, Hartl DL, Galagan JE, Lander ES, Wirth DF: A genome-wide map of diversity in Plasmodium falciparum. Nat Genet. 2007, 39 (1): 113-119. 10.1038/ng1930.View ArticlePubMedGoogle Scholar
- Mu J, Awadalla P, Duan J, McGee KM, Keebler J, Seydel K, McVean GA, Su XZ: Genome-wide variation and identification of vaccine targets in the Plasmodium falciparum genome. Nat Genet. 2007, 39 (1): 126-130. 10.1038/ng1924.View ArticlePubMedGoogle Scholar
- Jeffares DC, Pain A, Berry A, Cox AV, Stalker J, Ingle CE, Thomas A, Quail MA, Siebenthall K, Uhlemann AC, Kyes S, Krishna S, Newbold C, Dermitzakis ET, Berriman M: Genome variation and evolution of the malaria parasite Plasmodium falciparum. Nat Genet. 2007, 39 (1): 120-125. 10.1038/ng1931.PubMed CentralView ArticlePubMedGoogle Scholar
- Daly MJ, Rioux JD, Schaffner SF, Hudson TJ, Lander ES: High-resolution haplotype structure in the human genome. Nat Genet. 2001, 29 (2): 229-232. 10.1038/ng1001-229.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.